On the Record · Neurocrine Biosciences
Neurocrine Biosciences competitors, on the record
The companies Neurocrine Biosciences itself names as competitors in its annual reports, 2023 to 2025, each with the sentence it appears in and the filing it came from.
Who Neurocrine Biosciences names
| Company | Named in |
|---|---|
| Teva Pharmaceuticals Industries | 2025 |
In its own words
Teva Pharmaceuticals Industries
Word for word“INGREZZA competes with AUSTEDO (deutetrabenazine), marketed by Teva Pharmaceuticals Industries, for the treatment of TD in adults and chorea associated with Huntington's disease.” 10-K for 2025
Read from Neurocrine Biosciences’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-11. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.